Article
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series.
Cells - 31 Oct 2020
Palmerini Emanuela, Setola Elisabetta, Grignani Giovanni, D'Ambrosio Lorenzo, Comandone Alessandro, Righi Alberto, Longhi Alessandra, Cesari Marilena, Paioli Anna, Hakim Rossella, Pierini Michela, Marchesi Emanuela, Vanel Daniel, Pignochino Ymera, Donati Davide Maria, Picci Piero, Ferrari Stefano
Abstract excerpt
Background: The evidence on high-dose ifosfamide (HD-IFO) use in patients with relapsed osteosarcoma is limited. We performed a retrospective study to analyze HD-IFO activity. Methods: Patients with osteosarcoma relapsed after standard treatment [methotrexate, doxorubicin, cisplatin +/- ifosfamide (MAP+/-I)] with measurable disease according to RECIST1.1 were eligible to ifosfamide (3 g/m2/day) continuous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.